comparing two surfactant in management of respiratory distress syndrome in preterm infants

comparing the efficacy of two surfactant (alveofact, crusorf) in complications and duration of mechanical ventilation for management of respiratory distress syndrome in preterm infants

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212123915N8

Enrollment

Registered

2013-01-09

Start date

2012-09-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory distress syndrome. respiratory distress syndrome

Interventions

intratracheal alveofact 1.2 ml/ kg after diagnosis of RDS and repeat if needed every 12 hours till 3 doses

intratracheal crusorf 2.5 ml/kg at first dose and 1.25 ml/kg if repeated dose needed every 12 hours till 3 doses

Intervention 1: intratracheal alveofact 1.2 ml/ kg after diagnosis of RDS and repeat if needed every 12 hours till 3 doses. Intervention 2: intratracheal crusorf 2.5 ml/kg at first dose and 1.25

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: gestation age less than 32 weeks; birth weight less than 1500 gr exclusion criteria:congenital malformations; severe birth asphyxia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mechanical ventilation. Timepoint: daily for 7 days. Method of measurement: need for intubation and mechanical ventilation.	—

Secondary

Measure	Time frame
Mortality. Timepoint: daily tilldischarge. Method of measurement: death.;Complications. Timepoint: till discharge. Method of measurement: presence of pulmonary hemorrhage, bronchopulmonary dysplasia, air leak syndrome, retinopathy of prematurity, sepsis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManizheh Mostafa Gharehbaghi

Tabriz University of Medical SCiences

gharehbaghimm@yahoo.com+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026